Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 10.61 CAD 0.57% Market Closed
Market Cap: 261.7m CAD
Have any thoughts about
Profound Medical Corp?
Write Note

Profound Medical Corp
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Profound Medical Corp
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Profound Medical Corp
TSX:PRN
Change in Working Capital
-$947k
CAGR 3-Years
47%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Change in Working Capital
-$2m
CAGR 3-Years
3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Change in Working Capital
-CA$5.1m
CAGR 3-Years
-64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanalysis Scientific Corp
XTSX:NSCI
Change in Working Capital
-CA$3m
CAGR 3-Years
N/A
CAGR 5-Years
-26%
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Change in Working Capital
CA$234.9k
CAGR 3-Years
973%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
MedMira Inc
XTSX:MIR
Change in Working Capital
-CA$2.5m
CAGR 3-Years
N/A
CAGR 5-Years
-28%
CAGR 10-Years
5%
No Stocks Found

Profound Medical Corp
Glance View

Market Cap
259.8m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
5.8 CAD
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Profound Medical Corp's Change in Working Capital?
Change in Working Capital
-947k USD

Based on the financial report for Jun 30, 2024, Profound Medical Corp's Change in Working Capital amounts to -947k USD.

What is Profound Medical Corp's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
22%

Over the last year, the Change in Working Capital growth was 20%. The average annual Change in Working Capital growth rates for Profound Medical Corp have been 47% over the past three years , 22% over the past five years .

Back to Top